Why Did Europe Restrict Puberty Blockers? What Four Countries Decided

Key Takeaways
Why did Europe restrict puberty blockers? Finland, Sweden, Norway, and the United Kingdom each narrowed access after their own reviews found the evidence limited or insufficient. Their rules and reasons differ.
Finland's June 2020 recommendation put psychosocial support first. Sweden's December 2022 guidance allows hormonal treatment in "exceptional cases." England's National Health Service ended routine use in March 2024.
Sweden's board also cited rising diagnoses and reports of medical detransition, and said it could not assess how common detransition is.
The Endocrine Society said in May 2024 that the Cass Review contains no new research contradicting its guideline.
Norwegian physicians argued in 2025 that reviews called the evidence insufficient even though it shows puberty delay works.
Documents cited here say puberty blockers or puberty-suppressing hormones. This page says puberty-pausing medication, and all three names mean the same medicines.
The short answer
Europe did not adopt one policy on puberty blockers. Four countries narrowed access between 2020 and 2024, mainly because reviews rated the evidence on benefits as limited or insufficient, and the United Kingdom added a safety finding.
At TransHealthHub, we cover these decisions as evidence context. U.S. care follows U.S. law and clinical guidance, and our explainer on the Cass Review gives the wider background.
What each country decided
Country | Decision | Stated reason |
Finland | 2020: psychosocial support first; hormonal treatment before 18 only in defined circumstances | Research on minors is limited |
Sweden | December 2022: hormonal treatment in exceptional cases | Evidence insufficient; rising diagnoses; detransition |
Norway | 2023: review board urged treatment as research | Insufficient evidence |
United Kingdom | 2024: routine National Health Service use ended, supply ban made indefinite | Weak evidence; safety risk |
Finland's Council for Choices in Health Care recommended on June 16, 2020, that research data on treating minors is limited, that psychosocial support come first, and that surgery be excluded for minors. It also called for gender identity variation to be distinguished from typical adolescent exploration and for care to be centralized at two university hospitals.
Sweden's National Board of Health and Welfare, in December 2022, issued a weak negative recommendation, citing an assessment by the Swedish Agency for Health Technology Assessment that existing evidence is insufficient, and said treatments should be provided in the context of research. Reporting in The BMJ on March 23, 2023, Jennifer Block described Norway's Healthcare Investigation Board finding insufficient evidence and recommending that treatments be treated as under trial, with a national registry. A 2025 article in the Norwegian medical journal said health authorities in Norway have since tightened access.
Why the reasons differ
Certainty of evidence was the common thread, but not the only one. The Swedish board concluded that at group level the risks were likely to outweigh the expected benefits, while noting the efficacy and safety of treatments are not proven. In the United Kingdom, the policy of NHS England, published March 12, 2024, states these medicines are not available as a routine treatment. The Commission on Human Medicines then determined there was an unacceptable safety risk, and the government made its ban indefinite on December 11, 2024.
Our guide to systematic reviews explains how a low-certainty rating works. It signals that important questions remain. It does not by itself show harm, though the Swedish and British decisions included safety judgments beyond that.
What U.S. medical societies say
The American Medical Association, American Academy of Pediatrics, American Psychological Association, and the Endocrine Society regard this care as evidence-based and medically necessary, and oppose government interference in these decisions.
In a May 8, 2024 statement, the Endocrine Society said the Cass Review does not contain any new research that would contradict its guideline, which it describes as recommending a very conservative approach with no medical intervention before puberty. The American Medical Association said in April 2021 that medical decisions belong within the patient-physician relationship. The American Psychological Association, in a February 2024 policy, supports access to evidence-based care for transgender children, adolescents, and adults.
Not everyone in Europe agrees
Physicians in Norway have questioned the reasoning. Atle Fretheim, Anne Kveim Lie, and Ketil Slagstad wrote in the Norwegian medical journal in March 2025 that systematic reviews found strong evidence puberty-pausing medication delays puberty, the outcome young people said mattered most, yet still concluded the evidence was insufficient. They argue decision-makers overlooked patient priorities.
Frequently asked questions
Did all of Europe restrict puberty blockers? This page covers four countries and does not survey every one. Each acted on its own review.
Do these decisions apply in the United States? No. They are foreign health-system decisions, and the U.S. societies above continue to support this care.
Does low certainty mean the medication is unsafe? Not by itself. Certainty ratings describe the strength of research, and the sources above describe the separate safety judgments in their own words.
Further Reading and Resources
COHERE Finland (2020): recommendation summary
Swedish National Board of Health and Welfare (2022): guideline summary
Block, The BMJ (2023): Norway's guidance review
NHS England (2024): clinical policy
UK government (2024): indefinite ban announcement
Endocrine Society (2024): statement in support of care
Fretheim et al., Tidsskriftet (2025): on puberty suppression
TransHealthHub: guide to puberty-pausing medication
This page addresses a health topic and reflects the evidence as of September 2026. It is not medical advice. Decisions about a young person's care belong to that young person, their family, and their clinicians.



Comments